The expanded field rights significantly increase the optionality and peak-revenue potential of Spyre's lead asset SPY003. Watch for any early pipeline expansion into new indications (e.g., psoriasis, psoriatic arthritis, ankylosing spondylitis) and for any material transaction that would accelerate the timeline for dosing outside IBD.
SYRE drugs
SYRE drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $69.16entry
- T+1 · 6mo ago +6.30%α +7.00% · $73.52
- T+5 · 5mo ago +10.53%α +13.49% · $76.44
- T+20 · 5mo ago +28.53%α +30.09% · $88.89
- T+60 · 3mo ago +35.35%α +34.23% · $93.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics expanded its license agreement with Paragon Therapeutics, removing the previous restriction that limited SPY003 (an IL-23p19 antibody) to inflammatory bowel disease. The new 'Field' covers all therapeutic areas, subject to dosing restrictions: no combination-trial dosing outside IBD before June 2028 and no monotherapy dosing outside IBD before June 2030. This materially increases the total addressable market for Spyre's lead asset, though the near-term clinical focus remains IBD.
Key Facts
- License field expanded from inflammatory bowel disease to all therapeutic areas (prophylaxis, palliation, treatment, diagnosis of all human diseases).
- Monotherapy dosing outside IBD restricted until June 1, 2030; combination dosing outside IBD restricted until June 1, 2028.
- If Spyre or the retained IL-23 project licensee consummates a material transaction (change of control or sale of lead IL-23p19 asset post-Phase II), the monotherapy restriction outside IBD terminates early on June 1, 2028.
- Amendment effective May 29, 2026; filed June 1, 2026.
Financial Impact
No financial terms disclosed. The amendment expands the addressable market for SPY003 from IBD-only to all therapeutic areas, substantially increasing peak revenue potential.
Risk Factors
- Dosing restrictions outside IBD remain in place until 2028 (combination) and 2030 (monotherapy), limiting near-term clinical expansion.
- No financial terms disclosed, the amendment could carry undisclosed milestone or royalty adjustments.
- Clinical development in new indications carries inherent trial risk and regulatory uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000075 |
| Document: syre-20260529.htm | 0001636282-26-000075 |
| Document: 0001636282-26-000075-index-headers.html | 0001636282-26-000075 |
| Document: 0001636282-26-000075-index.html | 0001636282-26-000075 |
| Document: 0001636282-26-000075.txt | 0001636282-26-000075 |
Track record
36 reports on SYRE
7 of 11 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers